These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1523 related items for PubMed ID: 10368521

  • 1. Smoking and use of oral contraceptives: impact on thrombotic diseases.
    Lidegaard O.
    Am J Obstet Gynecol; 1999 Jun; 180(6 Pt 2):S357-63. PubMed ID: 10368521
    [Abstract] [Full Text] [Related]

  • 2. Estrogen and progestin components of oral contraceptives: relationship to vascular disease.
    Carr BR, Ory H.
    Contraception; 1997 May; 55(5):267-72. PubMed ID: 9220222
    [Abstract] [Full Text] [Related]

  • 3. Population-based study of risk of venous thromboembolism associated with various oral contraceptives.
    Farmer RD, Lawrenson RA, Thompson CR, Kennedy JG, Hambleton IR.
    Lancet; 1997 Jan 11; 349(9045):83-8. PubMed ID: 8996419
    [Abstract] [Full Text] [Related]

  • 4. Thrombotic diseases in young women and the influence of oral contraceptives.
    Lidegaard O.
    Am J Obstet Gynecol; 1998 Sep 11; 179(3 Pt 2):S62-7. PubMed ID: 9753312
    [Abstract] [Full Text] [Related]

  • 5. The use of oral contraceptives and the occurrence of acute myocardial infarction in young women. Results from the Transnational Study on Oral Contraceptives and the Health of Young Women.
    Lewis MA, Heinemann LA, Spitzer WO, MacRae KD, Bruppacher R.
    Contraception; 1997 Sep 11; 56(3):129-40. PubMed ID: 9347202
    [Abstract] [Full Text] [Related]

  • 6. Oral contraception and risk of a cerebral thromboembolic attack: results of a case-control study.
    Lidegaard O.
    BMJ; 1993 Apr 10; 306(6883):956-63. PubMed ID: 8490470
    [Abstract] [Full Text] [Related]

  • 7. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen.
    Bloemenkamp KW, Rosendaal FR, Helmerhorst FM, Büller HR, Vandenbroucke JP.
    Lancet; 1995 Dec 16; 346(8990):1593-6. PubMed ID: 7500751
    [Abstract] [Full Text] [Related]

  • 8. Effects of smoking on prostacyclin formation and platelet aggregation in users of oral contraceptives.
    Roy S.
    Am J Obstet Gynecol; 1999 Jun 16; 180(6 Pt 2):S364-8. PubMed ID: 10368522
    [Abstract] [Full Text] [Related]

  • 9. Haemostasis profile in smoking and nonsmoking women taking low-dose oral contraceptives.
    Fruzzetti F, Ricci C, Fioretti P.
    Contraception; 1994 Jun 16; 49(6):579-92. PubMed ID: 8070263
    [Abstract] [Full Text] [Related]

  • 10. Estimates of the risk of cardiovascular death attributable to low-dose oral contraceptives in the United States.
    Schwingl PJ, Ory HW, Visness CM.
    Am J Obstet Gynecol; 1999 Jan 16; 180(1 Pt 1):241-9. PubMed ID: 9914611
    [Abstract] [Full Text] [Related]

  • 11. Oral contraceptives and venous thromboembolic disease: the findings from database studies in the United Kingdom and Germany.
    Farmer RD, Lawrenson RA.
    Am J Obstet Gynecol; 1998 Sep 16; 179(3 Pt 2):S78-86. PubMed ID: 9753314
    [Abstract] [Full Text] [Related]

  • 12. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components.
    Jick H, Jick SS, Gurewich V, Myers MW, Vasilakis C.
    Lancet; 1995 Dec 16; 346(8990):1589-93. PubMed ID: 7500750
    [Abstract] [Full Text] [Related]

  • 13. Modern oral contraceptives and cardiovascular disease.
    Rosenberg L, Palmer JR, Sands MI, Grimes D, Bergman U, Daling J, Mills A.
    Am J Obstet Gynecol; 1997 Sep 16; 177(3):707-15. PubMed ID: 9322646
    [Abstract] [Full Text] [Related]

  • 14. The influence of thrombotic risk factors when oral contraceptives are prescribed. A control-only study.
    Lidegaard O.
    Acta Obstet Gynecol Scand; 1997 Mar 16; 76(3):252-60. PubMed ID: 9093141
    [Abstract] [Full Text] [Related]

  • 15. A comparative metabolic study of two low-estrogen-dose oral contraceptives containing desogestrel or gestodene progestins.
    Crook D, Godsland IF, Worthington M, Felton CV, Proudler AJ, Stevenson JC.
    Am J Obstet Gynecol; 1993 Nov 16; 169(5):1183-9. PubMed ID: 8238183
    [Abstract] [Full Text] [Related]

  • 16. First-time use of newer oral contraceptives and the risk of venous thromboembolism.
    Suissa S, Blais L, Spitzer WO, Cusson J, Lewis M, Heinemann L.
    Contraception; 1997 Sep 16; 56(3):141-6. PubMed ID: 9347203
    [Abstract] [Full Text] [Related]

  • 17. The risks of venous thromboembolic disease among German women using oral contraceptives: a database study.
    Farmer RD, Todd JC, Lewis MA, MacRae KD, Williams TJ.
    Contraception; 1998 Feb 16; 57(2):67-70. PubMed ID: 9589831
    [Abstract] [Full Text] [Related]

  • 18. The oral contraceptive user.
    Lidegaard O, Overgaard K, Hauch O.
    Acta Obstet Gynecol Scand; 1988 Feb 16; 67(1):27-31. PubMed ID: 3176910
    [Abstract] [Full Text] [Related]

  • 19. Effect of oral contraceptive progestins on serum copper concentration.
    Berg G, Kohlmeier L, Brenner H.
    Eur J Clin Nutr; 1998 Oct 16; 52(10):711-5. PubMed ID: 9805216
    [Abstract] [Full Text] [Related]

  • 20. Cardiovascular disease: pathogenesis, epidemiology, and risk among users of oral contraceptives who smoke.
    Castelli WP.
    Am J Obstet Gynecol; 1999 Jun 16; 180(6 Pt 2):S349-56. PubMed ID: 10368520
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 77.